• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Curetis

edit

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.

Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Milestones

edit

• 
  Curetis added Johannes Bacher as Director Operations, Managing Director.
  Posted 12/3/09 at 5:45pm
• 
  Curetis added Andreas Boos as Director R&D, Managing Director.
  Posted 12/3/09 at 5:45pm
• 
  Curetis received $13.4M (€9.6M) in Series A funding. (10/26/11)
  Posted 10/26/11 at 7:38pm via curetis.com
• 
  Curetis received $6.38M (€4.5M) in Series A funding. (5/17/11)
  Posted 10/26/11 at 7:38pm via curetis.com
• 
  Curetis received $1.85M (€1.5M) in Series A funding. (5/31/10)
  Posted 5/26/11 at 5:28am via curetis.com
• 
  Curetis received $28M (€18.5M) in Series A funding. (12/3/09)
  Posted 12/3/09 at 5:45pm via curetis.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/4/09

Sources

1. € 18.5 million Series A Financing Round closed (curetis.com) [edit]
2. Curetis AG increases Series A Financing to € 20 Million and receives ISO 13485 Certification (curetis.com) [edit]
3. Curetis AG successfully increases Series A financing round to EUR 24.5 million (curetis.com) [edit]
4. Series A financing round expended to 34.1 euro (curetis.com) [edit]